Related Experiment Videos
Hyperlipidemia in hypertension: causes and prevention
1Columbia University, New York, NY.
Insights
Thiazide diuretics worsen hyperlipidemia in hypertension patients, potentially due to potassium or sodium loss. Sodium administration improved lipid levels, suggesting a role in metabolic tolerance for hypertension management.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Hyperlipidemia is common in hypertension patients, but the underlying cause remains unclear.
- Thiazide diuretics, used for hypertension, can exacerbate hyperlipidemia, possibly linked to electrolyte depletion.
Purpose of the Study:
- To investigate the role of hypokalemia in thiazide-induced hyperlipidemia.
- To examine the impact of sodium balance on lipid metabolism during hypertension treatment.
Main Methods:
- Assessed lipid concentrations using a spironolactone-thiazide regimen to prevent potassium loss.
- Measured lipid levels during periods of sodium administration and placebo therapy.
- Conducted a multicenter trial comparing enalapril and indapamide for resistant hypertension.
Main Results:
- Hyperlipidemia persisted despite normal serum potassium levels during spironolactone-thiazide treatment.
- Cholesterol levels decreased during sodium administration.
- Indapamide demonstrated superior antihypertensive potency with minor metabolic effects compared to enalapril.
Conclusions:
- Sodium administration appears to improve lipid metabolism, while sodium diuresis enhances antihypertensive effects.
- Low-dose combination therapy with a diuretic and a nondiuretic agent may improve metabolic tolerance and hypertension control.
- This therapeutic strategy shows promise for optimizing cardiovascular risk reduction.
Abstract:
Hyperlipidemia is prevalent in hypertension, but the cause of this association is unknown. Treatment of hypertension with thiazide diuretics accentuates the hyperlipidemia, perhaps by causing potassium or sodium depletion. To assess the role of hypokalemia in thiazide hyperlipidemia, I measured lipid concentrations while using a spironolactone-thiazide regimen to prevent potassium wastage during the treatment of hypertension. Blood pressure decreased substantially, but hyperlipidemia occurred despite the maintenance of normal serum potassium. To test a role of sodium balance, I measured lipid levels during periods of sodium feeding and placebo therapy. Cholesterol levels decreased during sodium administration. Carrying this information to therapy, I participated in a multicenter comparison of enalapril and indapamide therapy in resistant hypertension. Both regimens caused minor metabolic effects, but indapamide provided superior antihypertensive potency. This evidence suggests that sodium feeding improves lipid metabolism, but sodium diuresis enhances an antihypertensive effect. Low-dose therapy combining a diuretic, such as indapamide, with a nondiuretic agent promises to improve metabolic tolerance and maximize hypertension control. This strategy optimally lowers overall cardiovascular risk.